Exploration of scaffolds from natural products with antiplasmodial activities, currently registered antimalarial drugs and public malarial screen data by Egieyeh, Samuel et al.
molecules
Article
Exploration of Scaffolds from Natural Products with
Antiplasmodial Activities, Currently Registered
Antimalarial Drugs and Public Malarial Screen Data
Samuel Egieyeh 1, James Syce 2, Alan Christoffels 1 and Sarel F. Malan 2,*
Received: 9 November 2015; Accepted: 12 January 2016; Published: 16 January 2016
Academic Editors: James W. Gauld, Leif A. Eriksson and Derek J. McPhee
1 South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute,
University of the Western Cape, Cape Town 7535, South Africa; segieyeh@sanbi.ac.za (S.E.);
alan@sanbi.ac.za (A.C.)
2 School of Pharmacy, University of the Western Cape, Cape Town 7535, South Africa; jsyce@uwc.ac.za
* Correspondence: sfmalan@uwc.ac.za; Tel.: +27-21-959-3190; Fax: +27-21-959-3407
Abstract: In light of current resistance to antimalarial drugs, there is a need to discover new classes
of antimalarial agents with unique mechanisms of action. Identification of unique scaffolds from
natural products with in vitro antiplasmodial activities may be the starting point for such new
classes of antimalarial agents. We therefore conducted scaffold diversity and comparison analysis
of natural products with in vitro antiplasmodial activities (NAA), currently registered antimalarial
drugs (CRAD) and malaria screen data from Medicine for Malaria Ventures (MMV). The scaffold
diversity analyses on the three datasets were performed using scaffold counts and cumulative scaffold
frequency plots. Scaffolds from the NAA were compared to those from CRAD and MMV. A Scaffold
Tree was also generated for each of the datasets and the scaffold diversity of NAA was found to be
higher than that of MMV. Among the NAA compounds, we identified unique scaffolds that were not
contained in any of the other compound datasets. These scaffolds from NAA also possess desirable
drug-like properties making them ideal starting points for antimalarial drug design considerations.
The Scaffold Tree showed the preponderance of ring systems in NAA and identified virtual scaffolds,
which may be potential bioactive compounds.
Keywords: natural products; antimalarial drugs; scaffold diversity; scaffold tree
1. Introduction
There is considerable interest to address the challenge of discovering new and novel
small-molecule pharmaceuticals in view of the minimal success of compounds in combinatorial
libraries to yield blockbuster drugs [1]. Natural products however remain a rich source of biologically
active substances [2–5] and have made significant contribution to the antimalarial arsenal [6]. Based
on this and the recent significant contribution of artemisinin, a natural product, to the antimalarial
armoury, natural products with antiplasmodial activities (NAA) reported in literature [7,8] may be
potential resources for discovery or design of new classes of antimalarial drug candidates. A new
class of antimalarial drugs, preferably with a novel mechanism of action that could circumvent the
current resistance profile of Plasmodium (the causative organism of malaria) is highly desirable and
needed. Since the molecular scaffolds as well as the pharmacophore features of a compound define
the uniqueness of a compound, exploration of scaffolds of NAA may lead to identification of new
antimalarial chemotypes. The term molecular scaffold is used to describe the core structure of a
molecule and it determines the spatial orientation within the binding pocket of biological targets [9].
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Hence, compounds with similar pharmacophore features but different scaffolds may have different
bioactivity or mechanism of action (MOA).
It is believed that natural products are a good source of novel molecular scaffolds [10–15] and
scaffolds derived from natural compounds have preferable or privileged scaffold architectures [16].
Since the scaffolds of natural compounds are potentially valuable, assessing the scaffold diversity of
NAA and comparing them to CRAD and MMV is a logical starting point for identification of scaffolds
that are meaningful for antimalarial drug design/discovery. Such scaffolds may be starting points for
new classes of antimalarial drug candidates.
Scaffold diversity is one of many parameters that may be used to characterize compound
libraries [17] and assess chemical diversity based on the scaffolds and ring systems in
structures [1,18–21]. In order to analyze the scaffold diversity of a compound library, a suitable
representation of a scaffold is needed. One of these representations is the Murcko framework/scaffold,
proposed by Bemis and Murcko [22], which has been used to analyze the structures of known drugs
and identify the common features in screening libraries and natural products [14,23]. The Murcko
framework (Figure 1e) of a structure consists of all the ring systems and all the linkers that connect the
ring systems [24]. This framework is obtained by pruning all side-chain atoms, i.e., non-ring atoms not
on a direct path between two ring systems (Figure 1) [1,24]. The method separates molecules into ring
systems (Figure 1a), linkers (Figure 1b), side chain atoms (Figure 1c), and the framework (Figure 1d),
which is the union of ring systems and linkers in a molecule. A Murcko framework (Figure 1e) keeps
information on atom type, whereas a graph framework (Figure 1f) reduces all atoms to carbon and
all bonds to single bonds. The Murcko framework defines only molecular topology and contains
no three-dimensional or stereochemical information [1]. The frequency of Murcko frameworks or
scaffolds have been used to define the structural diversity of chemical databases [1].
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A number of studies have been carried out to explore the scaffold diversity of compound sets
based upon the frequency of Murcko scaffolds and to identify unique scaffolds. For example, Bemis and
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Murcko used the Murcko scaffold to establish the scaffold diversity of 5129 known drugs and identified
1179 scaffolds [22]. An analogous analysis of the Chemical Abstracts Service (CAS) Registry of over
million compounds also indicated that a large percentage of organic compounds are embodied by only
a small percentage of scaffolds [25]. An analogous conclusion was drawn from a study that looked at
the co-occurrence of scaffolds in a chemical database [26]. The study found that specific scaffolds and
combinations of scaffolds were far more frequent than others and were therefore termed “Chemical
Clichs” [26]. In a study that explored scaffolds present in a set of approximately 150,000 bioactive
compounds, only 780 simple aromatic scaffolds were uncovered [19]. In another study, analysis of
scaffold diversity of seven representative commercial and proprietary compound libraries revealed
only a small number of well represented scaffolds and a high percentage of singleton scaffolds [24].
With specific reference to natural products, Grabowski and Schneider [14] have reviewed structural
diversity of molecular frameworks and scaffolds of collections of drugs and drug-like molecules,
pure natural products, and natural product derived compounds. Among the natural product library,
they identified more than one thousand scaffolds that were not contained in any other compound set
analyzed [27]. Although Lee and Schneider [10] demonstrated, using self-organizing maps (SOM),
that current trade drugs and natural products have several topological pharmacophore patterns in
common, they showed that only 17% of the scaffolds found in natural products could be found in
registered drugs [10].
Another way to analyze the scaffold diversity of a compound library is with Scaffold Trees.
Wetzel et al. [28] used the Scaffold Tree technique for chemoinformatic analysis of natural products.
The technique iteratively removes rings one by one according to a set of prioritization rules, and in the
end, the substructure with only one ring is obtained. Scaffold Hunter has been used to achieve this
task for large datasets [29]. Scaffold Hunter, an interactive tool for intuitive hierarchical structuring,
visualization and analysis of complex structure and bioactivity data, is used for navigation in and
exploration of chemical space to identify “virtual scaffolds” that should share bioactivity properties
with their parent compound or child scaffolds [29]. These virtual scaffolds are chemically meaningful
entities that may provide opportunities for the identification of new biologically relevant scaffold
classes [29].
The goal of this study was to use the methods described above to systematically identify and
compare the scaffolds from NAA, CRAD and MMV. Specific objectives included analysis of the
scaffold diversity of each dataset and exploration of similarity/diversity amongst scaffolds from NAA,
CRAD and MMV. The relationship between the antiplasmodial activities and scaffold diversity of
the NAA was explored by comparing the scaffold diversity of the bioactivity subgroups of NAA
(i.e., highly active (IC50 < 1 µm), active (IC50: 1–5 µm), moderately active (IC50: 5–10 µm) and low
activity (IC50 > 10 µm)). From this study, we identified novel scaffolds in NAA that may be used as
strategic and guiding frameworks for design of a natural product inspired antimalarial compound
library. Interestingly, we observed greater scaffold diversity in the highly active subgroup of the NAA.
2. Results and Discussion
2.1. Scaffold Diversity
Scaffold counts and Cumulative Scaffold Frequency Plots (CSFP) were used to assess the scaffold
diversity of three datasets: natural products with antiplasmodial activity (NAA), currently registered
antimalarial drugs (CRAD) and malarial screen data from Medicines for Malaria Venture (MMV). In
addition, the scaffold diversities of the highly active (HA), active (A), moderately active (MA) and low
active (LA) subgroups of NAA were explored.
Molecules 2016, 21, 104 4 of 14
2.1.1. Higher Scaffold Diversity Observed for the NAA Dataset
Scaffold Counts and Cumulative Scaffold Frequency Plots (CSFP)
Scaffold counts enumerate the number of compounds included in the analysis (M) and the
number of scaffolds (Ns) as well as the number of singleton scaffolds (Nss) generated from such
compounds. With regards to the analysis of Level 1 scaffolds (from Scaffold Tree) for natural products
with antiplasmodial activity (NAA), currently registered antimalarial drugs (CRAD) and malarial
screen data from Medicines for Malaria Venture (MMV), Table 1 shows the ratios of scaffolds to
molecules (Ns/M), singleton scaffold to molecules (Nss/M) and singleton scaffolds to total scaffolds
(Nss/Ns). Higher values of these ratios are indicative of the greater scaffold diversity of the dataset.
Applying these metrics to the Level 1 scaffolds, the MMV and NAA data sets showed a lower ratio
of scaffolds to molecules (Ns/M = 0.11 and 0.29, respectively) compared to CRAD (Ns/M = 0.59).
A similar trend was observed with the singleton scaffold to molecules (Nss/M). This indicates that
MMV and NAA data sets contain heavily represented scaffolds. In other words, for MMV there are
10 molecules for every scaffold, 3.3 molecules for every scaffold in NAA while for CRAD there are
1.8 molecules for every scaffold. This result suggests that CRAD has the greatest scaffold diversity
amongst these datasets. The inherent bias in this dataset is however that limited numbers of molecules
from specific scaffolds are normally taken through the drug development pipeline.
Table 1. Parameters from the scaffold diversity analysis of CRAD, NAA and MMV (using Level 1 scaffolds) 1.
Ns/M Nss/M Nss/Ns P25 P50 P75 AUC
Currently registered
Antimalarial Drugs (CRAD) 0.59 0.48 0.81 6.47 17.97 49.91 6794
Natural products with in vitro
antiplasmodial activity (NAA) 0.29 0.17 0.57 1.65 6.75 27.58 8017
Malarial screen data from
Medicines for Malaria Venture (MMV) 0.11 0.05 0.53 0.11 1.02 9.39 9043
1 The parameters include ratios of scaffolds to molecules (Ns/M), singleton scaffolds to molecule (Nss/M),
singleton scaffolds to total scaffolds (Nss/Ns), percentage of scaffolds that represent 25% of molecules (P25),
percentage of scaffolds that represent 50% of molecules (P50), percentage of scaffolds that represent 75% of
molecules (P75) and area under curve (AUC).
The ratio of singleton scaffolds to scaffolds (Nss/Ns) provides more information on the distribution
of molecules over scaffolds. For example, in CRAD with the highest ratio of scaffolds to molecules
(Ns/M = 0.59), suggesting that the data set has high scaffold diversity, the proportion of singleton
scaffolds to scaffolds (Nss/Ns) is 0.81; therefore, 81% of scaffolds (13 scaffolds) represent only
1 molecule each, and 19% of scaffolds (3 scaffolds) represent the remaining 14 molecules. This indicates
that a large proportion of the Level 1 scaffolds in CRAD are singletons, suggesting that the distribution
of molecules over scaffolds is uneven. In comparison, the NAA and MMV data sets showed lower
ratio of singleton scaffolds to scaffolds (Nss/Ns = 0.57 and 0.53, respectively), indicating that a lower
proportion of their Level 1 scaffolds are singletons and a more even distribution of molecules over
scaffolds. This observation may be expected since NAA and MMV are screening collections containing
a selection of antiplasmodial compounds that are equally represented.
Cumulative Scaffold Frequency Plots (CSFP) gives an indication of the distribution of compounds
over the molecular scaffolds [24]. It was generated by plotting percentage of scaffolds against
percentage of molecules as detailed in the experimental section. CSFP are interpreted thus: A diagonal
line point to an equal distribution of compounds across the molecular scaffolds, while curves that
are above the diagonal line (i.e., with steeper gradients) represents compound datasets with low
molecular scaffold diversity. The Pn values (n = 25%, 50% and 75%) and the area under the curve
(AUC) are quantitative parameters estimated from the CSFP. The Pn values (where n is 25%, 50%, and
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75%) indicate the percentage of scaffolds that represent “n” percent of compounds; thus, P50 is the
percentage of scaffolds that represent 50% of all compounds in the dataset.
The Cumulative Scaffold Frequency Plots (CSFP) of the Level 1 scaffolds for NAA, CRAD and
MMV are shown in Figure 2 while the Pn values (where n is 25%, 50%, and 75%) and the AUC are
included in Table 1. In the extreme case of scaffold diversity, each molecule in the collection will have
its own scaffold, the plot would be a diagonal line from [0%, 0%] to [100%, 100%]; therefore, the closer
the curve is to the diagonal line, the greater the diversity of the dataset. The result (Figure 2) showed
that CRAD was closest to the diagonal line, indicative of its relatively higher scaffold diversity. MMV
dataset was furthest from the diagonal line hence had the least scaffold diversity. The CSFP for NAA
was between that of CRAD and MMV suggesting that the NAA dataset had higher scaffold diversity
than MMV but lower scaffold diversity than CRAD. Since CSFP gives an indication of the distribution
of compounds over the molecular scaffolds [24], the result also attests that compounds from NAA are
more evenly distributed over their scaffolds than compounds from MMV but less evenly distributed
than compounds from CRAD. Another point of note is that all curves began with a very steep gradient;
this indicates the presence of scaffolds that represent a large proportion of the dataset. The shallow
region of the curve represents the high proportion of singleton scaffolds.
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In all, the proportion of scaffolds present in a dataset (Ns/M), proportion of singleton scaffolds
(Nss/Ns) and the Cumulative Scaffold Frequency Plots (CSFP) were useful indicators of the scaffold
diversity of the datasets studied. The greatest scaffold diversity was observed in CRAD. This result
is expected, as mentioned earlier, since the CRAD dataset represents selected compounds that came
from diverse chemical screening libraries during drug development and have successfully made it
to market as antimalarial drugs. A more interesting conclusion from these results is that scaffolds
from NAA (a collection of only natural compounds active against Plasmodium) were more diverse than
those from MMV (a collection of synthetic and natural compounds active against Plasmodium). The
lower scaffold diversity observed for MMV may be attributed to the synthetic compounds, which
have low scaffold diversity, within this collection of compounds [30]. The low scaffold diversity of
synthetic compounds stems from the nature of medicinal chemistry research over the past few decades,
which has focused upon familiar and limited sets of biological targets as well as feasible chemical
synthesis [30]. Consequently, these synthetic compounds may be intrinsically biased towards feasible
chemical synthetic pathways and known bioactivity chemical space.
Scaffold diversity has been reported to be most crucial to the functional diversity of a collection
of compounds. Although functional group substituents are important for interaction or binding with
macromolecules, the central scaffold of a compound determines its spatial orientation and shape-space
coverage [30]. Therefore, the higher scaffold diversity of NAA over MMV suggests that NAA may
cover a wider biological chemical space than MMV. The potential to cover uncharted regions of the
antimalarial chemical space increases the prospect of discovering potential antimalarial drugs with
novel mechanism of antimalarial bioactivity. In conclusion, the higher scaffold diversity of NAA thus
increases the likelihood to detect hit compounds with novel mechanism of action.
2.1.2. Bioactivity Subgroups of NAA (HA, A, MA and LA)
Scaffold Counts and Cumulative Scaffold Frequency Plots (CSFP)
The scaffold count parameters obtained for the comparison of the subgroups of NAA (highly
active (HA), active (A), moderately active (MA) and low active (LA)), using Murcko scaffolds, are
outlined in Table 2. Though HA had the highest proportion of scaffolds to molecules (Ns/M = 0.66),
there was no significant difference amongst the Ns/M ratios of HA, A (0.60) and MA (0.64) except for
LA (0.52) (p = 0.001). The ratio of singleton scaffolds to total scaffolds (Nss/Ns) was between 0.6 and
0.75 for the subgroups of NAA. This indicates that a high proportion of scaffolds were singletons and
were not uniformly distributed across the HA, A, MA and LA datasets.
Table 2. Parameters from the scaffold diversity analysis of CRAD and the subgroups of NAA (HA, A,
MA and LA) (using Murcko scaffolds).
Ns/M Nss/M Nss/Ns P25 P50 P75 AUC
CRAD 0.70 0.55 0.79 10.22 24.57 59.03 6247.6
HA 0.66 0.49 0.74 7.35 20.71 58.31 6410.2
A 0.60 0.40 0.67 6.59 18.96 54.50 6588.4
MA 0.64 0.49 0.77 6.16 18.53 55.68 6577.8
LA 0.52 0.38 0.73 4.19 13.96 46.50 7026.2
The parameters include ratios of scaffolds to molecules (Ns/M), singleton scaffolds to molecule (Nss/M),
singleton scaffolds to total scaffolds (Nss/Ns); percentage of scaffolds that represent 25% of molecules (P25),
percentage of scaffolds that represent 50% of molecules (P50), percentage of scaffolds that represent 75% of
molecules (P75) and area under curve (AUC) for analysis of CRAD and the subgroups of NAA.
Figure 3 shows the Cumulative Scaffold Frequency Plots (CSFP) for the Murcko scaffolds of the
subgroups of NAA (HA, A, MA and LA) and CRAD (as a locus). As expected, the plot for CRAD
was closest to the diagonal due to its high scaffold diversity. Amongst the subgroups of NAA, the
low active (LA) subgroup of the NAA data set was farthest from the diagonal line, indicating that it
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had the lowest scaffold diversity. There was an overlap of the CSFP of the other subgroups of NAA
(HA, A and MA). All the CSFPs level off early due to the high proportion of singletons in the datasets.
To decipher the order of scaffold diversity amongst the subgroups of NAA (HA, A and MA), the Pn
and AUC of the CSFP were estimated (Table 2). The larger the Pn values, the greater the scaffold
diversity and the lower the AUC, the greater the scaffold diversity. Amongst the subgroups of NAA,
the P25, P50 and P75 values for HA, A and MA were significantly higher than the LA. This suggests
greater scaffold diversity in HA, A and MA over LA. The AUC values for the subgroups of NAA
followed a similar trend as observed for the Pn values though in the reverse order; the smallest AUC
was observed in HA and the highest AUC in LA. In general, these results indicate the apparent scaffold
diversity amongst the activity subgroups of NAA and revealed an apparent correlation between
scaffold diversity and antiplasmodial activities (i.e., the greater the scaffold diversity, the broader the
antiplasmodial activities). Greater scaffold diversity suggests better coverage of chemical space and
thus increases the chance of finding compounds that interact with more biological targets to elicit
bioactivity. The relationship between scaffold diversity and the antiplasmodial activity of NAA is
thus clear.
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2.2. Molecular Similarity of Scaffolds Reveal Differences between the NAA and CRAD Datasets
In the quest to find unique scaffolds that are no present in currently registered antimalarial
drugs, we assessed the molecular similarity between the scaffolds obtained from currently approved
antimalarial drugs (CRAD), natural products with antimalarial activities (NAA) and the malarial
screen library from Medicines for Malaria Venture (MMV). We also took a closer look at the molecular
similarity between the scaffolds from CRAD and bioactivity subgroups of NAA (highly-HA, active-A,
moderat ly active-MA and l w active-LA).
Principal component analysis (PCA) was done to assess t e struct ral similarity amongst the
scaffolds from CRAD, NAA and MMV based on chemical bits-fingerprints. The results (Figure 4)
revealed that though most of the scaffolds from NAA occupy the same chemical space as scaffolds from
MMV, there were NAA scaffolds that were outliers from the main cluster. In comparison to scaffolds
from CRAD, the majority of the scaffolds from NAA occupied distinct regions of the molecular
similarity spac . These scaffolds from NAA are uniqu and are not present in scaffolds from CRAD.
The MMV also contain scaffolds that are located in different regions of the chemical space, suggesting
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that they are not present within the CRAD. Figure S1 contains a list of the NAA scaffolds that are not
present in CRAD.
A Self-Organizing Map (SOM) (Figure 5) was used to arrange scaffolds in a two dimensional
space in order to visualize similarity between CRAD and bioactivity subgroups of NAA (HA, A and
MA) as well as to identify unique scaffolds in these bioactivity subgroups. The SOM (Figure 5) showed
that some scaffolds from the bioactivity subgroups of NAA (HA, A and MA) occupied distinct regions
of the map where scaffolds from CRAD were not found. This suggests that these scaffolds are not
similar to the scaffolds from CRAD and thus unique to the dataset.
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subgroups of natural products with in vitro antiplasmodial activity (NAA): HA-highly active, A-active
and MA-moderately active. arkers represent scaffolds that are arranged in a two-dimensional space
based on scaffold structural similarity. The individual SOM clearly showed that scaffolds from the
NAA (HA, A and MA) occupied distinct regions of the SOM (in the upper quadrants and marked with
black rectangles) where scaffolds from CRAD are not found.
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Evaluation of the top twelve scaffolds (based on frequency of occurrence) from CRAD and HA
(Figure 6) revealed no similar scaffolds between these two scaffold sets. In all, given that unique
scaffolds may have unique orientation within drug targets [9] and thus unique mechanism of action,
these scaffolds may be explored as new frameworks for antimalarial drug design. In addition, Figure 7
showed that most of the scaffolds from NAA and MMV have drug-like properties (average hydrogen
bond acceptors less than 5, average hydrogen bond donors less than 2, average calculated logarithm of
partition coefficient less than 3 and average total molecular weight less than 200) that are far below the
cut-off recommended by Lipinski’s models [31,32].
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This “drug-likeness window” of scaffolds from NAA allows the addition of functional groups
unto these scaffolds, during the design of potential natural product based antimalarial drugs, without
exceeding the recommended drug-likeness cut-offs.
2.3. Scaffold Tree: Revealing Virtual Scaffolds
Scaffold Tree is a hierarchical classification of chemical scaffolds or ring systems from compounds
obtained by stepwise pruning of all terminal side chains and rings (Figure 8). The Scaffold Trees
for CRAD and subgroups of NAA (HA, A, MA and LA) datasets generated using Scaffold Hunter
are provided as portable data format files in the Figures S2–S6. These Scaffold Trees consist of
concentric circles with the parent compound and the scaffolds arranged along the outer and inner
circles respectively.
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Figure 8. A section of a Scaffold Tree generated with Scaffold Hunter for currently registered
antimalarial drugs (complete scaffold tree available in Figure S2). The technique first prunes all
terminal side chains from parent molecules (A); then iteratively removes rings one by one according to
a set of prioritization rules from the parent molecule (A) to get the intermediate scaffold (B); At the
end, the scaffold with only one ring (C) is obtained. Scaffolds B and C represent “virtual scaffolds” that
may have bioactivities similar to or higher than the parent compound (A).
The resulting Scaffold Trees of CRAD, A, MA and LA (Figures S2–S6) showed no scaffolds at
Level 5, Level 9, Level 10 and Level 11 respectively. However, HA had scaffolds at all levels of the
Scaffold Tree up to Level 11. The presence of scaffolds at increasing levels of the Scaffold Tree indicate
the predominance of ring systems and increasing molecular complexity of the compounds in a dataset.
These results therefore suggest that the NAA (HA, A, MA and LA) have greater molecular complexity
and more ring systems, as previously reported for natural products [33]. In addition, the most active
NAA i.e., HA may contain compounds with high molecular complexity and number of ring systems.
In addition, navigation of the building “scaffold” of the compounds in the datasets through the
Scaffold Tree enabled us to visualize “virtual scaffolds” that may share bioactivity properties with their
parent compound or child scaffolds [29]. These virtual scaffolds represent previously unexamined
molecules that may for example exhibit higher potency and thus provide opportunities to venture
into uncharted biologically relevant chemical space. These scaffolds may be of particular interest as
starting points for subsequent synthesis of the parent compounds.
In summary, the Scaffold Tree allowed the visualization of the complexity of the ring systems of
the compounds in the datasets analyzed. In addition, the Scaffold Tree contains “virtual scaffolds” that
are chemically meaningful entities and may provide new opportunities for the identification of new
bioactive compounds.
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3. Materials and Methods
3.1. Datasets for Scaffold Analysis
The scaffold analysis of three datasets were explored: natural products with in vitro antiplasmodial
activities (NAA) compiled from literature, PhD and Masters theses and public chemical databases;
currently registered antimalarial drugs (CRAD) from ChEMBL and malaria box from Medicines for
Malaria Venture (MMV). In total, there were 1036, 27, and 18923 compounds in NAA, CRAD and MMV,
respectively. Comparing a large collection of compounds to a small collection is not a concern because
studies have shown that large combinatorial libraries may contain a very low proportion of scaffolds
as compared to smaller collections [21,34,35]. The NAA was subdivided in four subgroups based
on their antiplasmodial activities (IC50): highly active (HA) (IC50: <1 µM), active (A) (IC50: 1–5 µM),
moderately active (MA) (IC50: 5–10 µM) and low activity (LA) (IC50: >10 µM).
3.2. Generation of Scaffolds and Scaffold Trees
Two scaffold representations were used to analyze the scaffold diversity of the three datasets:
Murcko scaffolds [22] and the Level 1 scaffolds from a Scaffold Tree [28], both of which are suitable for
compounds containing cyclic systems. Murcko scaffolds were generated using a Konstanz Information
Miner (KNIME) workflow [36]. The file containing the smiles and identifiers for each dataset were
read and converted to RDKit molecules [37]. The Murcko scaffolds were generated with the RDKit
“find Murcko scaffolds” [37] and written to a comma separated version file.
Scaffold Hunter was used to reduce each molecule in the dataset to its scaffold and arrange the
resulting scaffolds hierarchically in a Scaffold Tree [28]. Scaffold Trees (Figure 8) were generated for
CRAD, NAA (and its subgroups) and MMV. The molecules in each dataset were represented as the
leaf nodes of the Scaffold Tree. Lower levels of the Scaffold Tree were obtained by iterative removal
of rings according to a default rule set that are designed to retain the most richly functionalized ring
systems and are intended to be intuitive to a synthetic medicinal chemist [24]. This process continued
until only one ring remains at the root node of the tree (Level 0). The subsequent levels or nodes in the
tree are numbered starting from 1. Different molecules may have different levels, depending on the
complexity or the number of rings in the studied molecules; hence the number of levels of the Scaffold
Tree was counted for each dataset. The scaffolds at each level of the Scaffold Tree were also counted
for each data set.
The Level 1 scaffolds from the Scaffold Tree were used to assess the scaffold diversity of the
CRAD, NAA and MMV datasets because it has been reported to be most informative and appropriate
for such analysis [24]. The scaffolds at Level 0 were not chosen because they are usually too simple to
characterize the structural features of the studied molecules and at levels above Level 1, the scaffolds
become more complicated and even identical to the Murcko framework. In addition, some compounds
with low molecular weight or less molecular complexity usually do not have Level 3 or above. Murcko
scaffolds have been reported to be informative for Structural Activity Relationships (SAR) [22] and
was selected to evaluate the scaffold diversity and evaluate the association between scaffold diversity
and in vitro antiplasmodial activities for subgroups of NAA (HA, A, MA and LA).
3.3. Scaffold Diversity Analysis
Scaffold diversity was investigated using two parameters: Scaffold counts and Cumulative
Scaffold Frequency Plots (CSFP). These parameters provided information on the distribution of
molecules over scaffolds.
3.3.1. Scaffold Counts
The scaffold diversity analysis was performed on the CRAD, MMV, NAA and bioactivity
subgroups of NAA (HA, A, MA and LA) data sets. The numbers of unique scaffolds for each data
set were counted (Ns) along with the number of molecules they represent (M); this is referred to as
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the scaffold frequency. The number of singleton scaffolds was also recorded (Nss); singleton scaffolds
are scaffolds that are only present in one exemplar molecule. The ratio of scaffolds to compounds
(Ns/M) and the ratio of singleton scaffolds to all scaffolds (Nss/Ns) were used to assess the diversity
of scaffold space.
3.3.2. Cumulative Scaffold Frequency Plots (CSFP)
To generate cumulative scaffold frequency plots (CSFP), the scaffolds were first sorted by their
scaffold frequency (most frequent to least frequent). The cumulative percentage of scaffolds was
then plotted against the cumulative scaffold frequency as a percentage of total molecules. CSFP were
generated for CRAD, MMV and NAA using Level 1 scaffold representations. Murcko scaffolds were
used to construct the CSFPs for CRAD and bioactivity subgroups of NAA (HA, A, MA and N). From
the CSFPs, the percentages of scaffolds that represent “n” percent of compounds were determined
(where n = 25%, 50% and 75%). The area under the curve (AUC) was also estimated for each CSFP.
Both the P50 and AUC have been used as measures of scaffold diversity [24].
3.4. Molecular Similarity amongst Scaffolds
Self-Organizing Map [SOM], a robust artificial neural network algorithm, was used to organize
Murcko scaffolds of CRAD and bioactivity subgroups of NAA (HA, A, MA and LA) based on
scaffold structural similarity. Scaffold structural similarity was assessed with “Fragfp descriptors”
from DataWarrior [38]. Fragfp descriptors are substructure fragment dictionary based binary
fingerprints similar to MDL keys [39]. Principal component analysis [PCA] was used to assess
the structural similarity between Level 1 scaffolds from NAA and MMV. PCA was done on
“Skelspheres descriptors” generated for the NAA and MMV scaffolds with DataWarrior. “Skelspheres
descriptors” encodes circular spheres of atoms and bonds into a hashed binary fingerprint of 512 bits.
“Skelspheres descriptors” also account for stereochemistry, counts duplicate fragments and encodes
heteroatom-depleted skeletons. The first three principal components from the PCA were plotted in a
three dimensional graph. Scaffolds from NAA (HA, A, MA and LA) that are not similar to scaffolds
from CRAD may be novel in the antimalarial drug chemical space.
4. Conclusions
Murcko scaffolds and Scaffold Trees were generated from natural products with in vitro
antiplasmodial activities (NAA); currently registered antimalarial drugs (CRAD) and malaria box from
Medicine for Malaria ventures (MMV). The scaffold diversity of these antimalarial compound datasets
were computed and compared. The scaffold count and cumulative scaffold frequency plots (CSFP)
showed that CRAD is the most scaffold diverse dataset while NAA displayed more scaffold diversity
than MMV. Amongst the bioactivity subgroups of NAA, the high active (HA) compound set had the
highest scaffold diversity. The Scaffold count and Cumulative scaffold frequency plots (CSFP) were
useful indicators of scaffold diversity of the antimalarial and antiplasmodial datasets studied.
It was evident that many of the scaffolds from the NAA (HA, A, MA and LA) were not similar
to those from CRAD, thereby highlighting the novelty of these scaffolds in the antimalarial chemical
space. Moreover, most of the scaffolds have desirable drug-like properties and these novel scaffolds
may be used as frameworks to design new antimalarial focused compound libraries.
Scaffold Tree was also used to explore the scaffolds present in CRAD and bioactivity subgroups
of NAA (HA, A, MA and LA). The presence of scaffolds at increasing levels of the Scaffold Tree for
HA, A, MA and LA indicate the prevalence of ring systems and increasing molecular complexity of
the compounds in these datasets. More importantly, virtual scaffolds present at different levels of the
Scaffold Tree of the NAA compounds were identified, which are chemically significant, and may also
provide starting points for new potential antimalarial compounds.
Overall, the exploration and comparison of the scaffolds from CRAD, MMV and NAA (HA, A, MA
and LA) enabled us to find novel scaffolds and chemotypes that may result in progress towards design
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of new compound libraries and development drug candidates to combat malaria. This study also
underscores the potentially significant contributions from nature to antimalarial drug development.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/1/104/s1.
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